Addendum to Annual Report- Inclusion of Management Discussion & Analysis Report
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SPARC is circulating a revised Annual Report for FY 2024-25 after realizing that the Management Discussion and Analysis (MDA) section was accidentally left out of the version sent to shareholders on July 18, 2025. The addendum only adds back the MDA and does not change anything else, including the Notice of the 20th AGM. The newly included MDA outlines SPARC's sharper focus on oncology and immunology, with two anchor programs: SCD-153 (for Alopecia Areata, now in Phase 1b) and SBO-154 (an anti-MUC1 ADC for cancer, with USFDA IND clearance). It also confirms that Vodobatinib for Parkinson's disease (PROSEEK study) failed to meet its main goal and development has been paused, while Sezaby for neonatal seizures continues to progress. Revenue from operations dipped slightly to Rs 7,176.60 lakhs from Rs 7,554.53 lakhs, though losses narrowed compared to the previous year.
This is essentially a paperwork correction with no direct effect on the stock price or shareholder rights. However, the added MDA gives investors fuller visibility into the company's pipeline progress, strategic direction, and ongoing financial position, which can support better-informed investment decisions.